Aoife has been Vice President and Head of the Rare Disease Innovation Unit at Biogen since October 2015. In this role she leads a group of 40 scientists and physicians who focus on developing treatments for patients with rare genetic diseases. Prior to that she led the hematology clinical development group and was responsible for the development and approval of ALPROLIX and ELOCTATE and treatments for Hemophilia B and Hemophilia A. She continues to be responsible for all ongoing clinical studies and world-wide regulatory submissions in hemophilia. In addition, she oversees the Biogen collaborations with ISIS to develop SMNRx for SMA as well as our collaboration with Sangamo Biosciences, SOBI and AGTC.
Prior to joining Biogen, Aoife was Director of Clinical Development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 Diabetes. Aoife holds a medical degree from Trinity College Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.